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SUMMARY – Pituitary tumors account for more than 10% of all intracranial tumors. They of-
ten present with symptoms of hormonal hypersecretion, although they may also cause hypopituitari-
sm. Transsphenoidal pituitary surgery has become a commonly performed neurosurgical procedure, 
which has certain challenges for the anesthesiologist due to many distinct comorbidities associated 
with various adenomas. This article provides a review of  perioperative concerns regarding transsp-
henoidal pituitary surgery, encountered in a number of these patients. Thorough understanding of 
preoperative assessment, intraoperative management and potential complications is fundamental for 
successful perioperative patient care and avoidance of morbidity and mortality.  
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Introduction
Adenomas are usually histologically benign pitu-
itary neoplasms, which are the result of monoclonal 
expansion of one cell that underwent somatic muta-
tion. The usual opinion is that pituitary tumors are 
relatively rare and that they account for 10% of all in-
tracranial tumors; actually, however, they are much 
more common1,2. In 1981, Burrov et al. reported on 
pituitary adenomas found in 26.7% of non-selected 
autopsy materials3. Transsphenoidal approach to pitu-
itary tumors is a surgical method over 100 years old, 
which gained its popularity after Hardy and Guiot 
had reconfirmed and standardized it as a contempo-
rary microsurgical minimally invasive method4-6.
There is a constantly growing trend in the num-
ber of newly discovered pituitary tumors because of 
an enlarged number of educated endocrinologists, 
better availability of radioimmunoassay methods, and 
especially neuroimaging diagnostic methods7. The use 
of high-resolution neuroimaging methods, especially 
magnetic resonance imaging (MRI), has led to dis-
covery of incidental pituitary tumors of 3 mm in di-
ameter and bigger in about 20% of “normal” pituitary 
glands8.
Our experience in the management of patients un-
dergoing pituitary surgery is considerable. In 2008, 
1316 operations were performed at University Depart-
ment of Neurosurgery, Sestre milosrdnice University 
Hospital. There were 271 (20.6%) intracranial tumors, 
94 (34.7%) of these pituitary tumors9. 
The anesthesiologist must have due knowledge of 
anatomy, physiology, pathophysiology and endocrine 
function of the pituitary gland, and proper insight 
into the modern approach in pituitary surgery to be 
able to appropriately manage these complex patients. 
Thorough understanding of preoperative assessment, 
intraoperative management and potential complica-
tions is fundamental to successful perioperative pa-
tient care and avoidance of morbidity and mortality.      
Proper patient preparation for pituitary surgery 
requires teamwork, including an anesthesiologist, 
an endocrinologist and a neurosurgeon10. All pa-
tients require meticulous preoperative evaluation and 
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screening with special care to patients presenting with 
Cushing’s disease and acromegaly. 
The symptoms and clinical signs caused by pituitary 
tumors can be divided into two groups: those caused 
by autonomic hyperproduction of growth hormone 
(GH), prolactin (PRL), adrenocorticotropic hormone 
(ACTH), thyroid-stimulating hormone (TSH), fol-
licle-stimulating hormone (FSH) or luteinizing hor-
mone (LH); and those caused by compression of the 
surrounding structures and gland tissue by the tumor 
itself.     
Rarely, pituitary gland tumors present as apoplexy 
(bleeding inside the tumor) with hypopituitarism, 
sudden headache, signs of meningism, visual disor-
ders, ophthalmoplegia, or signs of intracranial expan-
sion. These situations are indications for immediate 
surgical treatment.
Strategies for optimal intraoperative anesthetic 
management should be carefully planned. Postop-
erative period necessitates careful monitoring of fluid 
balance and serum sodium because of an early diag-
nosis of diabetes insipidus and the syndrome of inap-
propriate antidiuretic hormone secretion (SIADH). 
Preoperative Patient Evaluation
Besides routine laboratory tests (complete blood 
count, electrolytes, coagulation tests, liver function 
tests, urinalysis), preoperative assessment of patients 
with pituitary tumors should include levels of pitu-
itary hormones and hormones of connected glands 
(women with secondary amenorrhea should always 
have pregnancy test done), cranial MRI, ophthalmic 
examination and evaluation for the signs of increased 
intracranial pressure (ICP)11. Detecting the abnor-
malities in thyroid function tests and abnormal func-
tion of adrenal glands is especially important. Levels 
of these affected hormones must be normalized before 
elective surgery. A routine, prophylactic administra-
tion of hydrocortisone to all patients with pituitary 
tumors is now avoided and it is given only to patients 
with low corticoid levels as substitution therapy11. 
Patients with acromegaly and Cushing’s disease of-
ten have other comorbidities and should be examined 
thoroughly. 
Even though pituitary surgery is typically per-
formed in an uninfected field, a swab of nasopharynx 
is obtained to confirm the absence of pathogens. 
Prolactinoma
Prolactinomas (tumors that produce hyperpro-
lactinemia) are the most common type of secretory 
(functioning) pituitary tumors. They mostly are mi-
croadenomas (less than 10 mm in diameter) that gen-
erally affect women. Macroadenomas (more than 10 
mm in diameter) are more often found in men and 
they usually cause visual abnormalities because of op-
tical nerve compression. To diagnose a prolactinoma, 
MRI must be positive and serum level of prolactin 
must be more than 20 ng/mL (400 mU/L). Nonfunc-
tioning tumors may also increase the level of prolactin 
compressing the pituitary stalk (“stalk effect”). This 
way they reduce the inflow of dopamine (which is a 
prolactin-inhibiting hormone) from hypothalamus to 
the pituitary gland. The first method in treating pro-
lactinomas is administering dopamine agonist bro-
mcriptine and the alternative cabergoline. Bromcrip-
tine can cause serious hypotension during anesthesia 
and other side effects such as nausea, vomiting and 
congestion of nasal mucosa. In case of resistance to 
medical therapy with dopamine agonists or its poor 
tolerance, occurrence of neurologic symptoms or 
spontaneous cerebrospinal fluid (CSF) leakage, surgi-
cal treatment is indicated12.  
Adenoma Secreting GH
Adenomas that secrete GH are often large and 
result in acromegaly (when present in adults) or gi-
gantism (when present in prepubertal patients causing 
excessive growth prior to epiphyseal fusion)13. Clini-
cal signs of acromegaly are enlarged mandible, hands, 
feet, growth of soft, connective tissue and signs of 
peripheral nerve compression14,15. It is also very often 
accompanied by diabetes mellitus and hypertension, 
premature coronary disease and cardiomyopathy in 
some patients. Because of enlarged fingers, pulse oxi-
metry may be difficult to perform. Proximal myopa-
thy and chest deformity can compromise respiratory 
function, especially in the early postoperative period. 
Soft tissue of the mouth, tongue, pharynx, epiglot-
tis and vocal cords, and laryngeal cartilage are also 
affected2. Anatomical features that are often pres-
ent in these patients are macroglossia, macrognathia 
and prognathism15. Paresis of the recurrent laryngeal 
nerve can be seen16. One fourth of patients with acro-
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megaly have an enlarged thyroid gland that compress-
es the trachea. All of these features make intubation 
difficult and demanding thorough airway evaluation 
prior to the induction of anesthesia, and action ac-
cording to the algorithm for difficult or impossible 
intubation if needed17. If in doubt, indirect laryngos-
copy is recommended. After adenoma resection, vocal 
cords regain normal structure and function in about 
10 days2. Obstructive sleep apnea (OSA) can affect 
up to 70% of these patients and can lead to a high 
perioperative risk. OSA is complicated by the risk of 
perioperative airway compromise, especially in early 
postoperative period and preoperatively due to ben-
zodiazepines and/or narcotics given as premedication. 
In these patients, caution is warranted when admin-
istering narcotics and benzodiazepines, which should 
always be done in the presence of qualified personnel. 
Also, patients with chronic untreated OSA have an 
increased risk of developing right heart failure due to 
pulmonary hypertension18. One third of acromegalic 
patients have hypertension15. Myocardial hypertro-
phy and fibrosis reduce function of cardiac ventricles, 
which can persist after the surgery2. The risk of death 
due to cardiovascular and respiratory disease (insuf-
ficiency) is increased compared with healthy subjects. 
Diabetes mellitus or glucose intolerance is often pres-
ent in acromegalic patients and hypoglycemic episodes 
may occur after surgery.
Tumors Secreting ACTH
Cushing’s disease is characterized by hypersecre-
tion of adrenocorticotropic hormone (ACTH) by 
pituitary adenoma and by clinical signs of corticoid 
excess: glucose intolerance or diabetes mellitus, amen-
orrhea, hypernatremia, hypokalemia, metabolic alka-
losis, hypertension, left ventricle hypertrophy, ECG 
changes, acne, abdominal striae, hirsutism, bruises, 
central obesity (“moon face” and “buffalo torso”), os-
teoporosis, proximal myopathy, muscle wasting and 
weakness, sleep apnea, kidney stones, gastroesopha-
geal reflux and mental status changes.
Therapy with metyrapone or ketoconazole can re-
duce the effects of excess cortisol, which has a high 
perioperative morbidity and mortality. Activation of 
renin-angiotensin-aldosterone system and enlarged 
blood volume cause hypertension in 80% of cases of 
Cushing’s disease2. Heart ultrasound in these patients 
shows left ventricle hypertrophy and asymmetric sep-
tal hypertrophy19. ECG changes that occur are inver-
sion of T waves and high voltage QRS complexes. All 
of these changes are normalized after the surgery. 
Sleep apnea is also often present.
Glucose intolerance is found in 60% and diabe-
tes mellitus in one third of patients, and is caused by 
lower rate of insulin secretion and higher resistance of 
insulin receptors2,14.  
Patients with Cushing’s disease tend to have hy-
pokalemic metabolic alkalosis resulting from miner-
alocorticoid activity. These abnormalities should be 
corrected preoperatively with supplemental potassium 
and spironolactone13. Advanced osteoporosis can cause 
fractures due to inappropriate patient positioning on 
the operating table. Obesity and gastroesophageal re-
flux are often found in these patients, so routine pre-
treatment with H2 antagonists and occasionally with 
metoclopramide is advised. A high serum concentra-
tion of glucocorticoids causes immunosuppression, 
which makes these patients susceptible to infection.
Because of the adipose tissue excess on the arms, 
an appropriate size cuff must be prepared for accurate 
blood pressure measurements. Adipose tissue, fragile 
skin and blood vessels due to hypercortisolism can 
make intravenous access technically difficult. 
Tumors That Secrete TSH, FSH and LH
Tumors that secrete TSH are very rare (2.8% of all 
pituitary tumors) but aggressive and are always treated 
surgically. They cause hyperthyroidism with elevated 
serum levels of TSH.
Adenomas that secrete FSH and LH cause pre-
mature puberty or menstrual bleeding in menopause 
and hypogonadism in men. They account for 15% to 
as much as 40% of all pituitary adenomas and it is 
thought that 80% of clinically nonfunctional pituitary 
tumors are gonadotropine-derived20. 
Nonfunctioning Tumors
Nonfunctioning tumors compress gland tissue 
and cause hypofunction. They can also cause apoplexy 
(bleeding within the pituitary gland) or Sheehan’s 
syndrome (postpartum infarction of the pituitary 
gland). Therapy is surgery or radiotherapy. They make 
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20%-25% of all pituitary tumors. First symptoms are 
often visual disturbances, headache and diabetes in-
sipidus; large tumors can cause signs of increased ICP 
and panhypopituitarism. Cortisol deficit and hypona-
tremia must be corrected before the surgery.
Surgical Approach
Transsphenoidal approach via endoscopic or mi-
crosurgical method is used in over 95% of pituitary 
tumors and has significantly lower rates of morbidity 
and mortality5. Surgical approach via bifrontal cran-
iotomy is more demanding and often results in long 
term hormone substitution. Since convulsions can oc-
cur after such an approach, anticonvulsants are given 
as premedication in our hospital. 
Anesthetic Management
The main goal of anesthetic management is to 
maintain hemodynamic stability, preserve adequate 
cerebral oxygenation and perfusion, secure appropri-
ate positioning of the patient, facilitate surgical expo-
sure, provide rapid awakening after the surgery, and 
assess neurologic functions21,22.  
Supplementation of glucocorticoids in patients 
with hypopituitarism is started on the evening before 
the operation with 100 mg of hydrocortisone i.v., sec-
ond dose is given just before or at the beginning of the 
operation, and the third dose is given on the evening 
after the operation (between 4.00 and 6.00 p.m.). This 
is a rather traditional approach that is still often used 
and is thought to markedly overtreat patients. Recom-
mendations for perioperative management of gluco-
corticoid therapy include performance of 0800 hour 
cortisol test and short ACTH 1-24 (Synacthen) test to 
prove ACTH deficiency. If test results are abnormal, 
the patient should be commenced on standard main-
tenance doses of glucocorticoid (15-30) mg hydrocor-
tisone daily while waiting for surgery. These patients 
should be given supraphysiological glucocorticoid 
cover for 48 hours perioperatively using hydrocorti-
sone 50 mg i.v. every 8 hours on day 0, 25 mg i.v. every 
8 hours on day 1, and 25 mg i.v. at 0800 hours on day 
218. If ACTH 1-24 test is normal, no perioperative 
glucocorticoid cover is needed. However, if selective 
adenomectomy is not possible and surgery is exten-
sive, glucocorticoids are instituted. All patients with 
Cushing’s disease require perioperative glucocorticoid 
cover. 
Intravenous antibiotic prophylaxis in our hospital 
includes cefuroxime 1.5 g or amoxicillin clavulan-
ate 1.2 g given prior to induction of anesthesia and 
for the next 24 h. This single-agent antibiotic covers 
gram-positive organisms most frequently found on 
pharyngeal mucosa. In 2010, the Croatian national 
guidelines for antimicrobial prophylaxis in surgery 
were published and their recommendation for antimi-
crobial prophylaxis in pituitary surgery is cefazolin 1 
g i.v. plus clindamycin 600 mg i.v. preoperatively and 
8 hours after the surgery23.
Careful investigation of the airways before the 
surgery, especially in patients with acromegaly, is re-
quired because of the reasons explained above. Four 
degrees of difficult airways have been defined in acro-
megalic patients: first degree represents no difficulty, 
second degree represents hypertrophy of nasal and 
pharyngeal mucosa with normal vocal cords and glot-
tis, third degree includes stenosis of the glottis and/or 
vocal cord paresis and, finally, fourth degree includes 
pharyngeal mucosal hypertrophy, abnormalities of the 
glottis and soft tissue around it18. In patients catego-
rized as having third and fourth degree of difficult air-
ways, flexible fiberoptic intubation is recommended.
After intubation, a pharyngeal pack must be 
placed to limit the risk of aspiration and filling of the 
stomach with blood and debris, which can lessen the 
likelihood of nausea and vomiting postoperatively. 
Topical application of local anesthetics and vaso-
pressor solutions to the mucosal surface of the nose is 
employed during surgical preparation. Most preferred 
are lidocaine-epinephrine mixtures. The routine use 
of relatively large quantities of these mixtures can re-
sult in significant systemic effects like arterial hyper-
tension and cardiac dysrhythmias. Fortunately, these 
effects are transient and should be treated with short 
acting agents. Excessive use of vasoconstrictors may 
cause systemic vasoconstriction, which can produce 
significant increase in afterload. Cases of myocardial 
ischemia have also been reported.
Some surgeons place an intrathecal catheter in 
order to manipulate CSF pressure and facilitate tu-
mor resection. This is usually done in patients with 
large tumors with suprasellar extension. The catheter 
is usually placed at the L3-L4 interspace. This allows 
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for 5-10 mL boluses of saline or air to increase CSF 
pressure and produce prolapse of large tumors into the 
intrasellar operative field. If air is used, nitrous oxide 
must be discontinued to avoid an increase in ICP and 
development of expanding pneumocephalus. 
For transsphenoidal surgical approach, the pa-
tient is positioned in a semi-recumbent position with 
the head elevated above the heart to facilitate venous 
drainage. The neck is extended and the head is turned 
slightly to the side to facilitate surgical access to nasal 
cavity. Endotracheal tube (ETT) and breathing tubes 
should be carefully fixed to prevent dislodgement of 
ETT because it is inaccessible during the operation.
All patients should have graded compression 
stockings during the surgery to prevent venous pool-
ing in lower extremities, venous thrombosis and pul-
monary embolism. 
Anesthetic Technique
Anesthetic technique and the choice of anesthetic 
agents are similar to other intracranial surgeries. Also, 
anesthetic selection depends on the patient’s comor-
bidities, neurologic disease, allergies and anesthetic 
history. Maintenance of anesthesia using ether, total 
intravenous anesthesia or balanced anesthesia with 
inhalation agent, muscle relaxant and opioid depends 
on the anesthesiologist’s individual preference24. In 
the presence of signs of raised ICP, nitrous oxide is 
avoided18. Although volatile anesthetics desflurane, 
sevoflurane and isoflurane raise ICP by increasing ce-
rebral blood flow (isoflurane least of all), their effect 
is time-dependent and with continued administra-
tion blood flow returns to normal. Also, simultaneous 
hyperventilation and administration of these volatile 
agents prevent increases in ICP13. Some authors advo-
cate maintaining anesthesia with intravenous agents in 
the situation of raised ICP18. The proximity of cranial 
nerves II-VI to the pituitary makes early postopera-
tive assessment of their integrity very important. To 
facilitate rapid emergence from anesthesia, a rapidly 
metabolizing agent such as propofol and remifentanil 
(remifentanil is not yet available in Croatia), or inha-
lation agents with low blood solubility such as sevo-
flurane or desflurane should be used. If remifentanil is 
used, a longer-acting opioid should be used to provide 
analgesia at the end of the surgery (when remifenta-
nil is discontinued) to prevent complicated emergence 
because of pain. Neuromuscular blockade needs to be 
maintained during the procedure to prevent any pa-
tient’s movements, which could lead to serious injury. 
Since the head is elevated above the level of the heart, 
there is a possibility of air embolism if a lesion of cav-
ernous sinus occurs. In this case, it is important to 
discontinue nitrous oxide. There is a minimal blood 
loss during transsphenoidal surgery; however, it could 
be catastrophic if carotid artery is injured. Therefore, 
all patients should have large-bore intravenous access 
for rapid volume resuscitation.
After removal of the tumor, Valsalva maneuver 
may be utilized to test for CSF leak. Sella is then 
packed with autologous fat before it is reconstructed. 
Monitoring
Monitoring includes ECG, pulse oximetry, end-tid-
al CO2, noninvasive arterial blood pressure, respiratory 
volumes and pressures. Patients with Cushing’s disease 
and, to a lesser extent, patients with acromegaly may 
present with significant cardiovascular disease, which 
together with intraoperative hemodynamic changes 
represent anesthetic risk. In these patients, invasive 
arterial blood pressure monitoring is necessary and it 
enables an early detection of hypo- and hypertension 
and their immediate treatment. Cardiac drug therapy 
should be continued until the time of surgery and again 
as soon as oral intake begins after the surgery. Routine 
placement of arterial catheters and central intravenous 
access should be omitted2,21. If tumor location is such 
that it compromises visual field, visual evoked potential 
(VEP) monitoring can be used, but extraordinary sen-
sitivity of VEP to anesthetics, high incidence of false-
negative and false-positive results have made VEP un-
necessary and costly18,21.
Intraoperative Complications
Complications during transsphenoidal approach 
are rare and are usually due to lesion of the surround-
ing structures, i.e. carotid artery, cranial nerves II-VI, 
venous sinuses and optic nerves and chiasm. Tran-
scranial approach carries risks like all other cranioto-
mies. Convulsions can occur and anticonvulsant pro-
phylaxis is a prudent choice. Anosmia is also possible 
because of the lesion of olfactory nerve. 
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Emergence
At the end of the surgery, pharyngeal packs are 
removed and mouth cavity suctioned. Patient is extu-
bated after spontaneous breathing and reflexes have 
returned. Rapid awakening facilitates immediate 
neurologic assessment but patient must be hemody-
namically stable and respiration sufficient. Straining 
or coughing should be minimal because it can precipi-
tate hemorrhage, CSF leakage and dislodgement of 
nasal tamponade.           
Acute Postoperative Care
The postoperative care after pituitary surgery re-
quires airway management, analgesia, close neuro-
logic and endocrine assessment, fluid balance control 
and monitoring for possible complications. Surgi-
cal complications include bleeding, CSF leak, visual 
changes and meningitis. Endocrine disorders that are 
commonly encountered are hypopituitarism, diabetes 
insipidus and SIADH.
All patients are at an increased risk of airway ob-
struction after transsphenoidal approach. Blood and 
secretions in the pharynx and nasal packs can com-
promise airway patency. Meticulous suctioning of 
oropharynx is necessary. Acromegalic patients with 
OSA have a high risk of respiratory obstruction as any 
other patient with OSA and should be closely moni-
tored. 
Pituitary surgery usually causes moderate pain but 
nasal packs can cause significant discomfort. Pain 
management in these patients includes non-steroid 
anti-inflammatory drugs, paracetamol and opioids if 
needed. 
Continuous neurologic assessment is necessary. 
Any cranial nerve palsy, visual change or mental sta-
tus changes should be addressed with imaging or re-
exploration.
Endocrine management in the postoperative peri-
od should consist of a team approach, which includes 
an endocrinologist, anesthesiologist and a surgeon. 
Again traditionally, hydrocortisone given preopera-
tively to patients with hypopituitarism is continued 
postoperatively for several days lowering the dose by 
25% each day until starting the oral dose of predni-
sone 20 mg in the morning and 10 mg in the eve-
ning. However, postoperative glucocorticoid replace-
ment should be decided based on 0800 hour plasma 
cortisol levels measured on days 1-3 for patients with 
normal ACTH 1-24 test results and on days 3-5 for 
those with abnormal test results. If cortisol level is 
<100 nmol/L, maintenance therapy with 15-30 mg/
day hydrocortisone is needed. For patients with cor-
tisol level of 100-250 nmol/L, 10-20 mg hydrocor-
tisone in a single morning dose should be given and 
further testing of hypothalamic-pituitary-adrenal 
(HPA) axis is required. In patients with cortisol level 
of 250-450 nmol/L, glucocorticoid replacement is 
needed during times of stress and they require fur-
ther HPA testing. Patients with cortisol level of 450 
nmol/L are not ACTH deficient18. If plasma cortisol 
levels after pituitary surgery in patients with Cush-
ing’s disease are low, they require physiologic hydro-
cortisone replacement therapy and a review of HPA 
axis. The aim is to gradually withdraw hydrocortisone 
as the ACTH suppression recovers25. Deficiencies in 
any pituitary hormone must be adequately replaced. 
Besides glucocorticoids, this most frequently involves 
thyroid hormone26.
Diabetes insipidus usually occurs in the first 24 
hours after the surgery and usually after more than 
80% of neurons producing vasopressin have been 
destroyed or functionally impaired. About 25% of 
postoperative patients have transitory diabetes insipi-
dus lasting for several days to weeks, and in 0.5% it 
stays permanent2,27. Symptoms that arise suspicion 
are polyuria (more than 2 mL/kg/h of urine output), 
hypotonic urine (specific gravity <1.005) and hyper-
natremia (>145 mmol/L). Urine output and its specific 
gravity must be monitored. Therapy is desmopres-
sin acetate 0.1 mcg i.v./i.m. and volume resuscitation 
(0.45% NaCl i.v. or H2O orally) with electrolyte mon-
itoring because desmopressin can cause significant 
hyponatremia.
SIADH is reported in 9%-25% of patients after 
transsphenoidal surgery and is usually manifested a 
week after the surgery2,28. It is characterized by in-
appropriate secretion of ADH regardless of plasma 
osmolarity, which causes low serum sodium (<135 
mmol/L), low serum osmolarity (<280 mOsmol/L) 
and concentrated urine with euvolemia (or slight hy-
pervolemia) and normal renal function. Since SIADH 
causes water retention in the body, first therapeutic 
measure is water restriction (800-1000 mL/day). If 
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significant hyponatremia (<120 mmol/L) is present, it 
should be treated with hypertonic saline (1.8% or 3%). 
Correction of serum sodium for severely symptomatic 
patients should be done at rates of 1-2 mEq/L/h for 3 
to 4 hours and then at a slower rate of 0.5 mEq/L/h 
(a total of 12 mEq/L over 24 hours) to avoid central 
pontine myelinolysis as a complication. The rate of 
sodium correction in asymptomatic patients is 0.5 
mEq/L/h (to a total of 10 mEq over 24 hours).
Cerebral salt wasting syndrome (CSWS) is a rare 
cause of hyponatremia and it should be distinguished 
from SIADH because restriction of water in this case 
can be deleterious to patients. This syndrome is found 
in patients with cerebral lesions when elevated urine 
output is present, and is characterized by hypona-
tremia and hypovolemia (opposite to SIADH).  Pa-
tients with CSWS have evidence of extracellular fluid 
depletion (negative fluid balance, low central venous 
pressure, increased urea, tachycardia, etc.) and treat-
ment is replacement of sodium and fluid losses.
Conclusion
Patients with pituitary tumors require a complex 
approach and coordination between the endocri-
nologist, the neurosurgeon and the anesthesiologist. 
Significant preoperative systemic manifestations and 
systemic diseases secondary to pituitary dysfunction 
should be controlled prior to surgery. Optimal in-
traoperative anesthetic management depends on the 
understanding of the patient’s disease and the require-
ments of pituitary surgery. Rapid emergence from 
anesthesia is important because early neurologic as-
sessment can reveal most common and most serious 
surgical complications. All patients require long-term 
follow-up with an endocrinologist to assess their hor-
monal status.  
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Sažetak
ANESTEZIJA KOD OPERACIJSKOG ZAHVATA NA HIPOFIZI
A. Horvat, † J. Kolak, A. Gopčević, M. Ilej i Ž. Gnjidić 
Tumori hipofize čine više od 10% svih intrakranijskih tumora. Oni se često manifestiraju simptomima hipersekrecije 
hormona, ali mogu isto tako izazvati hipopituitarizam. Transsfenoidna kirurgija hipofize postala je čest neurokirurški 
zahvat koji pred anesteziologa postavlja stanovite izazove zbog mnogih istodobno postojećih bolesti udruženih s raznim 
adenomima. Ovaj članak daje pregled pitanja koja treba razmotriti prije pristupanja transsfenoidnoj kirurgiji hipofize u 
većine ovih bolesnika. Potpuno razumijevanje prijeoperacijske procjene, intraoperacijskog zbrinjavanja i mogućih kompli-
kacija bitno je za uspješnu perioperacijsku skrb, kao i za izbjegavanje pobola i smrtnosti. 
Ključne riječi: Novotvorine hipofize – kirurgija; Anestezija; Prijeoperacijska skrb; Poslijeoperacijska skrb
